New Treatments Give Hope to Patients With One of the Deadliest Cancers

Pranathi Perati was running out of time to treat her stage-four pancreatic cancer when she found out she would get another shot: a clinical trial testing a new experimental drug.

Perati’s odds were slim—3% of late-stage pancreatic-cancer patients are still alive after five years. And half of all pancreatic-cancer patients live for less than a year after their diagnosis. For Perati, the drug, daraxonrasib from Revolution Medicines, has helped keep her alive for 17 months and counting.